Table 2 List of genetic association studies for chemotherapy-induced neuropathy in cancer patients, sorted by publication year and name of first author
From: Informative gene network for chemotherapy-induced peripheral neuropathy
Year | First author | Ethnicity | Cancer type | Sample size | Phenotype | Significant genes |
|---|---|---|---|---|---|---|
2003 | Aplenc R [41] | W, AA, H | Acute lymphoblastic leukemia | 533 | Peripheral neuropathy | CYP3A4, CYP3A5 |
2004 | Isla D [42] | W | Lung | 62 | Docetaxel-cisplatin-treated neurological | None |
2006 | Lecomte T [43] | W | Gastrointestinal solid tumors | 64 | Oxaliplatin-related cumulative neuropathy | GSTP1 |
2006 | Sissung TM [44] | W | N/A | 26 | Paclitaxel-induced neuropathy | ABCB1 |
2007 | Gamelin L [45] | W | Colon, rectum | 145 | Oxaliplatin-induced neurotoxicity | AGXT |
2007 | Marsh S [46] | N/A | Ovarian | 914 | Paclitaxel/docetaxel-induced neuropathy | None |
2007 | Oldenburg J [47] | W | Testicular | 238 | Self-reported chemotherapy-induced long-term toxicities | GSTP1 |
2007 | Ruzzo A [48] | W | Colorectal | 166 | Oxaliplatin-induced neurotoxicity | GSTP1 |
2008 | Keam B [49] | A | Gastric | 73 | Peripheral sensory neuropathy | None |
2008 | Pare L [50] | W | Colorectal | 126 | Cumulative oxaliplatin-induced neuropathy | None |
2008 | Sissung TM [51] | N/A | Prostate | 73 | Docetaxel-induced neuropathy | ABCB1 |
2009 | Argyriou AA [52] | W | Colorectal | 62 | Oxaliplatin-induced peripheral neuropathy | None |
2009 | Goekkurt E [53] | W | Gastric | 134 | Neurotoxicity | GSTP1 |
2009 | Green H [54] | W | Ovarian | 38 | Sensory/motor neuropathy | None |
2009 | Kim HS [55] | A | Epithelial ovarian | 118 | Taxane/platinum- induced neurotoxicity | ERCC1 |
2009 | Kweekel DM [56] | W | Colorectal | 91 | Neurotoxicity | None |
2009 | Mir O [57] | W | Breast, lung, prostate | 58 | Docetaxel(Taxotere)-induced peripheral neuropathy | GSTP1 |
2009 | Seo BG [58] | A | Gastric | 94 | Neuropathy | None |
2010 | Antonacopoulou AG [59] | W | Colorectal | 55 | Chronic oxaliplatin-induced peripheral neuropathy | ITGB3 |
2010 | Boige V [60] | W | Colorectal | 349 | FOLFOX-induced severe neurologic toxicity | None |
2010 | Chen YC [61] | A | Colorectal | 166 | Oxaliplatin-induced chronic cumulative neuropathy | GSTP1 |
2010 | Cho HJ [62] | A | Diffuse large B-cell lymphoma | 94 | Chemotherapy-related neurotoxicity | None |
2010 | Inada M [63] | A | Colorectal | 51 | Oxaliplatin-induced peripheral neuropathy | ERCC1, GSTP1 |
2010 | Kanai M [64] | A | Colorectal | 82 | Early-onset oxaliplatin-induced neuropathy | None |
2010 | Khrunin AV [65] | W | Ovarian | 104 | Cisplatin-based neuropathy | GSTM1, GSTM3 |
2010 | Li QF [66] | A | Gastric | 92 | Neurological toxicity | GSTP1 |
2010 | McLeod HL [67] | W, A, AA, H | Metastatic colorectal | 520 | Diarrhea, vomiting, paresthesia, febrile neutropenia and neutropenia | GSTP1 |
2010 | Ofverholm A [68] | W | Breast, ovarian | 36 | Occurrence and degree of neurotoxicity | None |
2010 | Rizzo R [69] | W | Breast | 95 | Taxane-induced hypersensitivity and sensory neuropathy | None |
2011 | Basso M [70] | W | Colorectal, pancreatic, bile ducts | 40 | Acute oxaliplatin neurotoxicity | SK3 |
2011 | Bergmann TK [71] | W | Ovarian | 119 | Sensory neuropathy | None |
2011 | Bergmann TK [72] | W | Ovarian | 92 | Sensory neuropathy | None |
2011 | Broyl A [73] | W | Multiple myeloma | 369 | Bortezomib/vincristine-induced peripheral neuropathy | RHOBTB2, CPT1C, SOX8, caspase 9, ALOX12, IGF1R, SOD2, MYO5A, MBL2, PPARD, ERCC4, ERCC3, AURKA, MKI67, GLI1, DPYD, ABCC1 |
2011 | Cibeira MT [74] | W | Multiple myeloma | 28 | Thalidomide-induced peripheral neuropathy | GSTT1 |
2011 | Corthals SL [75] | W | Multiple myeloma | 238 | Bortezomib induced peripheral neuropathy | CYP17A1 |
2011 | Favis R [76] | W | Myeloma | 139 | Bortezomib-induced peripheral neuropathy | CTLA4, PSMB1, CTSS, GJE1, DYNC1I1, TCF4 |
2011 | Hong J [77] | A | Colorectal | 52 | Sensory neuropathy | GSTP1 |
2011 | Johnson DC [78] | W | Multiple myeloma | 1495 | Thalidomide-related peripheral neuropathy | ABCA1, ICAM1, PPARD, SERPINB2, SLC12A6 |
2011 | Leskela S [79] | W | Lung, breast, ovary, uterus, head and neck | 118 | Neurotoxicity | CYP2C8, CYP3A5 |
2011 | Sucheston LE [80] | W, AA | Breast | 888 | Taxane-induced neurotoxicity | FANCD2 |
2012 | Baldwin RM [81] | W, AA, A | Breast | 855 | Paclitaxel induced peripheral sensory neuropathy | FGD4, FZD3, EPHA5 |
2012 | Braunagel D [82] | W | Acute myeloid leukemia | 360 | Cytarabine-induced neurotoxicity | NME1 |
2012 | Fung C [83] | W, A, AA, H | Testicular germ cell tumor | 137 | Cisplatin-induced neurotoxicity, peripheral neuropathy | None |
2012 | Hasmats J [84] | W | Ovarian, lung, carcinoma in uteri/peritoneal/breast | 94 | Paclitaxel/carboplatin-induced neuropathy | ABCA1 |
2012 | Hertz DL [85] | W, AA | Breast | 111 | Peripheral neuropathy | CYP2C8 |
2012 | Leandro-Garcia LJ [86] | W | Ovary, lung, breast | 214 | Paclitaxel-induced peripheral neuropathy | TUBB2A |
2012 | Won HH [87] | A | Colon | 96 | Severe oxaliplatin-induced chronic peripheral neuropathy | TAC1, FOXC1, GMDS, ITGA1, PELO, ACYP2, TSPYL6, DLEU7, BTG4, POU2AF1, CAMK2N1, FARS2, LYRM4 |
2013 | Argyriou AA [88] | W | Colorectal | 200 | Oxaliplatin-induced peripheral neuropathy | SCN4A, SCN10A |
2013 | Bergmann TK [89] | W | Ovarian | 241 | Paclitaxel induced neuropathy | None |
2013 | Cecchin E [90] | W | Colorectal | 144 | Oxaliplatin neurotoxicity | ABCC1, ABCC2 |
2013 | de Graan AJ [91] | W | Esophagus, ovary, cervix, endometrial, breast, lung, head/neck | 261 | Paclitaxel-induced neurotoxicity | CYP3A4 |
2013 | Hertz DL [92] | W, AA | Breast | 209 | Paclitaxel-induced neuropathy | CYP2C8 |
2013 | Kumamoto K [93] | A | Colorectal | 63 | Oxaliplatin-induced sensory peripheral neuropathy | GSTP1, GSTM1 |
2013 | Leandro-Garcia LJ [94] | W | Ovary, fallopian tube, peritoneum, lung, uterus, breast | 144 | Paclitaxel induced peripheral sensory neuropathy | EPHA4, EPHA6, EPHA5, XKR4, LIMK2 |
2013 | Lee KH [95] | A | Colon | 292 | Sensory neuropathy | XRCC1 |
2013 | Liu YP [96] | A | Gastric | 126 | Oxaliplatin-induced neurotoxicity | GSTP1 |
2013 | McWhinney-Glass S [97] | N/A | Ovarian | 404 | Platinum/taxane-induced neurotoxicity | SOX10, BCL2, OPRM1, TRPV1 |
2013 | Oguri T [98] | A | Colorectal | 70 | Oxaliplatin-induced chronic peripheral neurotoxicity | ACYP2, FARS2, ERCC1, TAC1 |
2014 | Abraham JE [99] | W | Breast | 1303 | Taxane-related sensory neuropathy | ABCB1, TUBB2A, CYP2C8, ABCC2, CYP1B1, KIAA0146-PRKD, SLCO1B1, EPHA6 |
2014 | Bhojwani D [100] | N/A | Acute lymphoblastic leukemia | 369 | Methotrexate-induced neurotoxicity | ASTN2, PXDC1, IYD |
2014 | Custodio A [101] | W | Colon | 206 | Oxaliplatin-induced peripheral neuropathy | CCNH, ABCG2 |
2014 | Hertz DL [102] | W, AA, A | Breast | 412 | Paclitaxel-induced peripheral neuropathy | CYP2C8, ABCG1 |
2014 | Khrunin AV [103] | W | Ovarian | 104 | Cisplatin-based neurotoxicity | None |
2014 | Lee SY [104] | A | Breast | 85 | Paclitaxel and gemcitabine combination chemotherapy neurotoxicity | RRM1 |